Streetbeat News

ATXI

Avenue Therapeutics, Inc.

https://www.avenuetx.com

Industry

Biotechnology

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.

Open

1.78

Mkt cap

3.7M

Volume

2.3K

High

1.84

P/E Ratio

0.07

52-wk high

26.48

Low

1.78

Div yield

N/A

52-wk low

1.60

Avenue Therapeutics has released its Q3 2024 financial results and highlighted recent corporate developments. The company anticipates topline data from its Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy by the end of 2024.

Portfolio Pulse from

November 14, 2024 | 9:15 pm

MIRA Pharmaceuticals shares surged 44.8% in pre-market trading after announcing a successful rat study with Ketamin-2. Other notable pre-market movers include MEDIROM Healthcare, Prestige Wealth, and Tevogen Bio, among others.

Portfolio Pulse from Avi Kapoor

August 26, 2024 | 9:58 am

Avenue Therapeutics (NASDAQ:ATXI) reported a Q2 EPS of $(6.43), significantly missing the analyst consensus estimate of $(1.05) by 512.38%. This represents an 83.4% improvement over the $(38.74) per share loss from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 8:10 pm

Avenue Therapeutics has completed the last patient visit in its Phase 1b/2a clinical trial of AJ201 for Spinal and Bulbar Muscular Atrophy.

Portfolio Pulse from Benzinga Newsdesk

May 16, 2024 | 12:32 pm

Avenue Therapeutics (NASDAQ:ATXI) reported a Q1 EPS of $(15.40), significantly missing the analyst consensus estimate of $(9.00) by 71.11%. This represents an 85.01% improvement over the $(102.75) per share loss from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 12:49 pm

Avenue Therapeutics plans to potentially offer shares of common stock up to a total of $3.9M through an agent, according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 8:56 pm

Clever Leaves Holdings Inc. announced its decision to voluntarily delist from Nasdaq, causing a 60% drop in its shares. Other stocks moved significantly in Monday's session, with Deciphera Pharmaceuticals surging 73% after an acquisition announcement, and various companies like Collective Audience and ImmunityBio also seeing substantial gains. Losers included Annovis Bio, down 57% after disappointing trial results, and Addex Therapeutics, falling 48.8% due to a failed epilepsy study.

Portfolio Pulse from Avi Kapoor

April 29, 2024 | 5:04 pm

Avenue Therapeutics (NASDAQ:ATXI) stock fell by 20.7% to $4.92 after announcing the exercise of warrants for $4.4 million in gross proceeds at a reduced price of $6.20 per share. The company will issue new Series C and D warrants as part of the transaction, expected to close by May 1, 2024. ATXI's stock has significantly declined over the past year, with a 93.29% decrease, and is currently considered oversold with an RSI of 27.91.

Portfolio Pulse from Henry Khederian

April 29, 2024 | 2:59 pm

Avenue Therapeutics' stock price has declined following the announcement of the exercise of warrants, resulting in $4.4 million in gross proceeds.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 1:04 pm

Avenue Therapeutics announced the exercise of warrants resulting in $4.4 million in gross proceeds. This financial move could indicate a strengthening of the company's cash position, potentially impacting its operational capabilities and future investment opportunities.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 12:14 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.